Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:45 ET | Source: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical...
November 03, 2025 10:41 ET | Source: Research and Markets

2 Day Virtual International Commercial Agreements Liabilities, Damages and other Contentious Issues Training Course (Dec 4th - Dec 5th, 2025)

Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Liabilities, Damages and other Contentious Issues in International Commercial Agreements Training Course (Dec 4th - Dec 5th, 2025)" training has been...
November 03, 2025 08:01 ET | Source: Prime Medicine, Inc.

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
October 23, 2025 03:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies

STEVENAGE, United Kingdom, Oct. 23, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is...
October 22, 2025 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. ...
October 21, 2025 16:04 ET | Source: NurExone Biologic Inc

NurExone Invited Presenter at Precision EV Forum in Cambridge, UK

TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing...
October 21, 2025 02:00 ET | Source: Spero Therapeutics, Inc.

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with...
September 22, 2025 16:10 ET | Source: GENFIT S.A.

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of...
September 22, 2025 16:10 ET | Source: GENFIT S.A.

GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société

Trésorerie et équivalents de trésorerie s’élevant à 107,5 millions d’euros au 30 juin 2025 n’incluant pas le paiement d’étape de 26,5 millions d’euros facturé en mai 2025 (reçu en juillet 2025) à la...
September 18, 2025 15:00 ET | Source: NVIDIA

NVIDIA Announces £2 Billion Investment in the United Kingdom AI Startup Ecosystem

News Summary: NVIDIA commits £2 billion to catalyze the U.K.’s AI startup ecosystem and accelerate the creation of new companies, jobs and globally transformative AI businesses.Accel, Air Street...